With a yearly death toll of 880,000, hepatitis B virus (HBV) remains a major health problem
worldwide, despite an effective prophylactic vaccine and well-tolerated, effective antivirals …

Hepatitis B virus (HBV) infection, although preventable by vaccination, remains a global
health problem and a major cause of chronic liver disease. Although current treatment …

Lack of detailed knowledge of SARS-CoV-2 infection has been hampering the development
of treatments for coronavirus disease 2019 (COVID-19). Here, we report that RNA triggers …

ABSTRACT ABI-H0731, a first-generation hepatitis B virus (HBV) core protein inhibitor, has
demonstrated effective antiviral activity in chronic hepatitis B (CHB) patients in a phase 1b …

Hepatitis B virus infection affects over 250 million chronic carriers, causing more than
800,000 deaths annually, although a safe and effective vaccine is available. Currently used …

Capsid assembly is a critical step in the hepatitis B virus (HBV) life cycle, mediated by the
core protein. Core is a potential target for new antiviral therapies, the capsid assembly …

The standard of care for the treatment of chronic hepatitis B (CHB) is typically lifelong
treatment with nucleos (t) ide analogs (NAs), which suppress viral replication and provide …

ABSTRACT NVR 3-778 is the first capsid assembly modulator (CAM) that has demonstrated
antiviral activity in hepatitis B virus (HBV)-infected patients. NVR 3-778 inhibited the …

Hepatitis B virus (HBV) affects an estimated 250 million chronic carriers worldwide. Though
several vaccines exist, they are ineffective for those already infected. HBV persists due to the …

Hepatitis B virus (HBV) is a major causative agent of human hepatitis. Its viral genome
comprises partially double-stranded DNA, which is complexed with viral polymerase within …